quinazolines has been researched along with T-Cell Lymphoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JH; Kim, WS; Park, C | 1 |
| Arribas, AJ; Berthold, M; Bertoni, F; Cascione, L; Gaudio, E; Gritti, G; Jourdan, T; Kwee, I; Lange, M; Liu, N; Margheriti, F; Politz, O; Rinaldi, A; Rossi, D; Scalise, L; Sperl, C; Spriano, F; Stathis, A; Sturz, A; Tarantelli, C; Zucca, E | 1 |
| Kasprzycka, M; Marzec, M; Odum, N; Ptasznik, A; Wasik, MA; Wlodarski, P; Zhang, Q | 1 |
| Bucki, R; El-Salem, M; Halasa, K; Kasprzycka, M; Liu, X; Marzec, M; Raghunath, PN; Wasik, MA; Wlodarski, P | 1 |
4 other study(ies) available for quinazolines and T-Cell Lymphoma
| Article | Year |
|---|---|
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Topics: Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Humans; Interleukin-6; Isoquinolines; Janus Kinase Inhibitors; Lymphoma, B-Cell; Lymphoma, T-Cell; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; STAT3 Transcription Factor; STAT5 Transcription Factor; Transfection; Tumor Suppressor Proteins | 2019 |
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2020 |
Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
Topics: Anaplastic Lymphoma Kinase; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Janus Kinase 3; Lymphoma, T-Cell; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor Protein-Tyrosine Kinases; STAT3 Transcription Factor | 2005 |
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Topics: Anaplastic Lymphoma Kinase; Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Immunohistochemistry; Lymphoma, T-Cell; Mitogen-Activated Protein Kinases; Models, Biological; Nuclear Proteins; Nucleophosmin; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transfection | 2007 |